MAIA Biotech highlights 12 patients enrolled in THIO-101 Phase 2 expansion, 30-month survival at SITC 2025

MAIA Biotechnology, Inc.

12 patients enrolled to date in Phase 2 THIO-101 expansion trial; sites now open in EMA countries, Turkey, and Taiwan.
Phase 3 THIO-104 screening has begun; CEO cites 17.8 months median OS observed in Phase 2 as potential basis for early FDA approval.
A patient treated in March 2023 showed survival of 30 months (912 days) as of September 17, 2025.
Posters presented at SITC 2025 detail Phase 2 and Phase 3 trial designs for ateganosine + cemiplimab in advanced NSCLC.
FDA has granted Fast Track designation for ateganosine in NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.